Antiviral Therapy in Patients With Influenza

Marie Welch, PharmD; Casey Mabus, PharmD; John A. (Jake) Galdo, PharmD, BCPS, BCGP


US Pharmacist. 2017;42(4):32-36. 

In This Article

Emergent Situations

Antiviral therapy may be in short supply during pandemics. If an emerging public-health threat is identified for which no licensed or approved product exists, the Project BioShield Act of 2004 authorizes the FDA Commissioner to issue an Emergency Use Authorization so that appropriate countermeasures can be taken quickly to protect the U.S. population's safety. However, in certain circumstances in which a commercial oral suspension is not available, the age-appropriate strength is not available, or other antiviral products are not available, oseltamivir (Tamiflu) may be extemporaneously prepared and administered through an NG/OG tube in order to meet the patient's needs.[26] If the commercially prepared oral suspension is not available, the manufacturer recommends compounding a 6 mg/mL suspension in emergency situations. See Table 3 and Table 4 for detailed information.